Published in Tumori on May 27, 2011
Drug induced rhabdomyolysis. Curr Opin Pharmacol (2012) 0.93
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med (2013) 0.86
Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori (2011) 0.85
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br J Cancer (2012) 0.75
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005) 4.48
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst (2006) 2.91
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol (2007) 2.19
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst (2008) 2.15
Cancer of unknown primary site. Lancet (2012) 2.07
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer (2007) 1.71
Cancer and pregnancy: poena magna, not anymore. Eur J Cancer (2005) 1.70
Old habits die hard: chest radiography for screening purposes in primary care. Am J Manag Care (2006) 1.50
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (2006) 1.43
Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst (2006) 1.42
CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature. Lung Cancer (2007) 1.39
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer (2012) 1.30
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev (2009) 1.25
Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev (2012) 1.24
Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat Rev (2009) 1.20
Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer (2010) 1.20
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res (2009) 1.17
Management of leptomeningeal malignancy. Expert Opin Pharmacother (2005) 1.17
Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol (2009) 1.15
Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol (2009) 1.13
Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol (2009) 1.09
Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev (2008) 1.08
Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev (2011) 1.05
Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat (2010) 1.05
Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J (2009) 1.05
Cancer of unknown primary site: missing primary or missing biology? Oncologist (2007) 1.03
Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treat Rev (2009) 1.03
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer (2005) 1.02
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol (2007) 0.97
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer (2009) 0.97
Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev (2008) 0.96
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat (2005) 0.95
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat (2011) 0.94
The pregnant mother with breast cancer: diagnostic and therapeutic management. Cancer Treat Rev (2005) 0.94
Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev (2013) 0.93
Successful publishing: how to get your paper accepted. Surg Oncol (2008) 0.93
Personality variables are associated with colorectal cancer patients' quality of life independent of psychological distress and disease severity. Psychooncology (2010) 0.92
Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer (2006) 0.92
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol (2014) 0.92
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer (2012) 0.91
Does psychological distress vary between younger and older adults in health and disease? J Psychosom Res (2011) 0.91
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol (2008) 0.90
Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev (2005) 0.90
Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest (2013) 0.90
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer (2009) 0.89
Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther Onkol (2014) 0.88
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med (2012) 0.88
Matrix metalloproteinases in carcinoma of unknown primary. Cancer (2005) 0.87
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res (2012) 0.87
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol (2004) 0.87
Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer (2004) 0.86
Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology (2013) 0.86
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer (2014) 0.85
Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev (2006) 0.85
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. Anticancer Drugs (2006) 0.85
Colorectal cancer screening awareness in European primary care. Cancer Detect Prev (2006) 0.85
Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis (2007) 0.84
Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders. Qual Life Res (2009) 0.84
Personality variables as predictors of early non-metastatic colorectal cancer patients' psychological distress and health-related quality of life: a one-year prospective study. J Psychosom Res (2010) 0.83
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res (2005) 0.83
Lung cancer during pregnancy: an emerging issue. Lung Cancer (2007) 0.82
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clin Exp Metastasis (2012) 0.82
Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer (2013) 0.82
Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J (2003) 0.81
Donor-derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res Treat (2008) 0.81
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective? Acta Oncol (2005) 0.81
Brain metastasis of unknown primary: a diagnostic and therapeutic dilemma. Cancer Treat Rev (2005) 0.80
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One (2013) 0.80
Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastasis (2012) 0.80
Anxiety, depression and defense mechanisms associated with treatment decisional preferences and quality of life in non-metastatic breast cancer: a 1-year prospective study. Psychooncology (2013) 0.79
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs (2002) 0.78
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol (2005) 0.78